Special notice
Notice of Intent - Sole Source for Pluvicto
36C25225F0191
Department of Veterans Affairs, 252-Network Contract Office 12. Pharmaceutical Preparation Manufacturing.
Awarded
Novartis Pharmaceuticals Corporation
$1,733,030.46 obligated so far on USAspending
Get the next one like this from Department of Veterans Affairs by email, the day it is posted.Find my opportunities
This one was awarded in 2025
9 like it are open now in pharmaceutical preparation manufacturing
- FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052
Department of Veterans Affairs, 250-Network Contract Office 10
Sources soughtNAICS 325412Anywhere in the US36C25027Q0052Closes in 2 daysNov 3 - Sacubitril/Valsartan Tablets (VA-27-00014055)
Department of Veterans Affairs, Nac Pharmaceuticals
PresolicitationNAICS 325412Anywhere in the US36E79727R0007Closes in 2 daysNov 3 - LIDOCAINE 5% PATCHES-REQUEST FOR INFORMATION
Department of Veterans Affairs, National Cmop Office
Sources soughtNAICS 325412Anywhere in the US36C77027Q0010Closes in 2 daysNov 3
Description
As published on SAM.gov.
The Department of Veterans Affairs, VHA Regional Procurement Office Central, Great Lakes Acquisition Center, Network Contracting Office 12, located at 115 S. 84th Street, Suite 101, Milwaukee, WI 53214-1476 intends to award a sole source, firm-fixed-price delivery order to Novartis Pharmaceuticals Corporation 59 Route 10, East Hanover, NJ 07936, for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan).
The associated North America Classification Systems (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing. The Edward J. Hines, Jr. VA Medical Center, 5000 South 5th Avenue, Hines, IL, 60141-3030, has a requirement for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) is a highly specialized radiopharmaceutical.
Pluvicto is a radiologic therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pluvicto is an FDA approved drug. Pluvicto manufactured and is a trademark of Novartis Pharmaceuticals Corporation.
This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. No solicitation documents are available at this time. Interested parties may give written notice to Parris.Weidenbach@va.gov by 5:00pm e.s.t. on 08/26/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement.
This information shall be provided at no cost or obligation to the Government. Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government. Inquiries shall be emailed to Parris.Weidenbach@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.
The contract, on USAspending
Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.
- Recipient
- Novartis Pharmaceuticals Corporation
- UEI
- NG61ZA8TADW3
- CAGE
- 04520
- Vendor location
- East Hanover, NJ
- Contract
- 36C25225F0191 under 36F79720D0180, delivery order
- Obligated
- $1,733,030.46, potential $2,175,871
- Actions
- 3 between August 27, 2025 and August 24, 2026
- Competition
- Full and Open Competition, 1 offer received
- Described as
- Delivery Order for a Base Plus One (1) Option Year for the Radiopharmaceutical Pluvicto.
- Match
- solicitation number 36C25225F0191 was reused as the contract number; same awarding office 36C252 (high confidence)
- Record
- USAspending award page
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
August 19, 2025
Special notice
Due August 26, 2025 at 5:00 PM EDT. SAM.gov, notice f825d9b28ccb45e79941db19db1b393f
Points of contact
- Parris S Weidenbach, Contract Specialistparris.weidenbach@va.gov414-844-4895